ERBB2 and gastric cancer: For instance, a bispecific antibody targeting both PD‐1 and TIGIT is currently being assessed in a phase II clinical trial for its efficacy and safety in the perioperative treatment of HER2‐positive, unresectable locally advanced GC in combination with trastuzumab and chemotherapy (NCT06630130).